Biotech General Discussion

Congrats to $ACAD, its investors, & Rett Syndrome patients on approval of DAYBUE (Trofinetide) for the treatment of Rett Syndrome • Rare genetic disease

• 1st approved drug

• Supported by Phase 3 Lavender trial data.

• No Black Box warning on label

• Nice stock runup to approval ~33%

• BPIQ Big Mover event

• ACAD gets FDA rare pediatric disease voucher

• Value ~$100M

Competitors from BPIQ Company Screener:

$TSHA

$AVXL

$JAZZ

Read more about upcoming PDUFAs

www.bpiq.com

Summary: The ACAD Trofinetide PDUFA is expected this Sunday March 12, 2023 Will we see an early decision before the weekend? See our full list of March PDUFAs HERE for BPIQ Pro Subscribers. Learn more about subscribing here! ACAD PDUFA ACAD's asset Trofinetide has a PDUFA target action date of March 12, 2023, this Sunday. We are interested to see if the FDA will announce an early decision on Friday, or if we will have to wait until Monday. This approval decision is a BPIQ Suspected Mover for Mar

FIrst posted 3/11/23

Not legal, tax or investment advice.

#ACAD #trofinetide